The U.S. Food and Drug Administration (FDA) has issued a safety alert regarding specific Impella CP Sets manufactured by Abiomed, a maker of mechanical circulatory support devices. According to the FDA’s medical device recall notice, affected units are out of specification and may result in low purge pressure events from the onset of clinical use, potentially compromising device function during active cardiac support.
Key takeaways
- Abiomed has initiated removal of specific Impella CP Sets with SmartAssist due to out-of-specification manufacturing
- The defect may cause low purge pressure events at the start of use, affecting pump performance
- The FDA alert highlights the importance of device manufacturer quality control in life-critical mechanical circulatory support systems
- Clinicians should verify device lot numbers and follow manufacturer guidance on affected units
Impella CP Device Safety Alert: Quality Control Pathway
Key stages in device detection, notification, and clinical response
Source: U.S. FDA Medical Device Recall Notice | Georgian Medical Journal News
What the defect means for mechanical circulatory support
The Impella CP is a percutaneously inserted left ventricular assist device (LVAD) used to provide hemodynamic support in patients with acute cardiogenic shock or during high-risk percutaneous coronary interventions. According to the FDA alert, the out-of-specification purge pressure—the pressurized saline flow that prevents blood clotting in the pump housing—creates risk of device malfunction at the critical moment of insertion and initiation of support.
Purge pressure is a fundamental safety feature in all mechanical circulatory support devices. Low or absent purge flow increases the risk of thrombotic occlusion within the pump, potentially leading to sudden loss of cardiac support. For patients in acute cardiogenic shock, such device failure during active support can result in rapid hemodynamic collapse.
Manufacturer action and clinical verification requirements
Abiomed’s decision to remove affected Impella CP Sets from circulation follows detection of the manufacturing defect. The FDA’s medical device recall system requires manufacturers to notify healthcare facilities and distributors of units involved. Clinical teams must cross-reference device lot numbers against the manufacturer’s advisory to identify potentially affected units before use. For units already implanted or deployed, clinicians should follow Abiomed’s specific guidance on monitoring and patient management protocols.
Quality control in life-critical device manufacturing
This alert underscores the critical importance of rigorous quality control in manufacturing mechanical circulatory support devices. The Impella CP operates under complex hemodynamic conditions, and even small deviations in component specifications—such as purge pressure calibration—can result in clinical risk. According to industry standards reviewed by the FDA’s Center for Devices and Radiological Health, mechanical circulatory support devices are subject to heightened post-market surveillance and mandatory adverse event reporting through the FDA’s Medical Device Reporting (MDR) system.
Specific Impella CP Sets manufactured by Abiomed are out of specification and may result in low purge pressure events from the onset of clinical use, creating risk of device malfunction during acute cardiac support.
— U.S. Food and Drug Administration, Medical Device Recall Notice
What this means
Frequently asked questions
What is the Impella CP, and when is it used?
The Impella CP is a percutaneously inserted left ventricular assist device (LVAD) that provides acute mechanical circulatory support. It is used primarily in patients with acute cardiogenic shock—a state of severe heart failure with inadequate blood flow—or during high-risk percutaneous coronary interventions in patients with reduced ejection fraction. The device is inserted via a catheter into the left ventricle and draws blood from the left ventricle, propelling it into the aorta to augment systemic perfusion.
What is purge pressure, and why is it critical?
Purge pressure refers to the controlled flow of pressurized saline through the pump housing to prevent thrombus (blood clot) formation on the internal surfaces of the device. Low or absent purge pressure increases the risk of thrombotic occlusion, which can cause acute device failure and loss of cardiac support. For patients in shock, such failure can be immediately life-threatening.
How should hospitals respond to this FDA alert?
Hospitals and cardiac catheterization laboratories should immediately review their inventory of Impella CP Sets, cross-reference lot numbers against the Abiomed/FDA advisory, segregate any affected units from clinical use, and notify their cardiology and cardiac surgery teams. For units already implanted, clinicians should contact Abiomed for specific monitoring and patient management recommendations. All adverse events should be reported to the FDA via the Medical Device Reporting (MDR) system.
The FDA and Abiomed continue to work together on post-market surveillance of mechanical circulatory support devices. Healthcare facilities are advised to maintain current communication with device manufacturers and monitor the FDA’s medical device safety alerts page for updates. As mechanical circulatory support becomes increasingly common in acute cardiac care, robust quality assurance and rapid communication of manufacturing defects remain essential to patient safety.
Source: U.S. FDA Medical Device Recall: Abiomed Impella CP Sets with SmartAssist
Was this article helpful?
Related Coverage
